Cardiovascular Diseases Clinical Trial
Official title:
Effects of Chronic Energy Drink Consumption on Cardiometabolic Endpoints
NCT number | NCT03840863 |
Other study ID # | 19-02 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 6, 2019 |
Est. completion date | July 30, 2020 |
Verified date | November 2020 |
Source | University of the Pacific |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many people use energy drinks (EDs) regularly, but the overall health concerns are still unknown. There are many energy drink products that contain a mixture of caffeine and other energy-boosting ingredients and supplements which can affect parameters related to the heart, blood pressure and blood glucose. Several previous studies have shown that energy drinks may affect heart rhythm and blood pressure significantly. As energy drinks are sugar-sweetened beverages, long-term use may also affect the body's metabolism, including cholesterol, blood sugars, and weight. The purpose of this study is to learn if drinking energy drinks everyday may affect a person's cardiometabolic health.
Status | Completed |
Enrollment | 15 |
Est. completion date | July 30, 2020 |
Est. primary completion date | June 20, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Healthy adults aged 18 - 40 years - Participants willing to adhere to study drink schedule (28 days) Exclusion Criteria: - Naïve caffeine consumers (< 2 cups of coffee [or equivalent caffeine intake] per week) - Chronic medical conditions including cardiovascular disease (known history of cardiac arrhythmias, family history of premature sudden cardiac death before age 60, cardiomyopathy, atherosclerosis), smoking, renal or hepatic dysfunction - Prolonged corrected QT (QTc) interval - History of substance abuse, including alcohol - Concurrent use of prescription drugs or over-the-counter products that may interact with study drinks (with the exception of oral contraceptives that have been used for over 1 month) - Baseline Blood Pressure greater than 140/90 mmHg - Baseline fasting blood glucose greater than 126 mg/dL or random blood glucose greater than 200 mg/dL - Females only: pregnancy or lactation, or planning to get pregnant within next 28 days |
Country | Name | City | State |
---|---|---|---|
United States | University of the Pacific | Stockton | California |
Lead Sponsor | Collaborator |
---|---|
University of the Pacific |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in blood pressure before and 1 hour after energy drink consumption | Measuring acute changes in peripheral systolic blood pressure before and 1 hour after energy drink consumption | 1 hour | |
Primary | Change in blood pressure before and after 4 weeks of energy drink consumption | Measuring chronic changes in peripheral systolic blood pressure before and 4 weeks after energy drink consumption | 4 weeks | |
Secondary | Change in QTc Interval before and after 1 hour of energy drink consumption | Measuring change in QTc interval via electrocardiogram before and after 1 hour of energy drink consumption | 1 hour | |
Secondary | Change in QTc Interval before and after 4 weeks of energy drink consumption | Measuring change in QTc interval via electrocardiogram before and after 4 weeks of energy drink consumption | 4 weeks | |
Secondary | Change in fasting blood glucose before and after 4 weeks of energy drink consumption | Measuring the change in fasting blood glucose before and after 4 weeks of energy drink consumption | 4 weeks | |
Secondary | Change in fasting lipid panel parameters before and after 4 weeks of energy drink consumption | Measuring the changes in total cholesterol (TC), high-density lipoprotein (HDL), triglyceride (TG), and calculated low-density lipoprotein (LDL-C) levels before and after 4 weeks of energy drink consumption | 4 weeks | |
Secondary | Change in Body Mass Index before and after 4 weeks of energy drink consumption | Measuring the change in Body Mass Index (BMI) before and after 4 weeks of energy drink consumption | 4 weeks | |
Secondary | Change in Body Fat Analysis before and after 4 weeks of energy drink consumption | Measuring the changes in Body Fat Analysis before and after 4 weeks of energy drink consumption, including percentage of body fat, fat mass, muscle mass, and fat in trunk | 4 weeks | |
Secondary | Change in Serum Creatinine before and after 4 weeks of energy drink consumption | Measuring the change in Serum Creatinine before and after 4 weeks of energy drink consumption | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|